Perianal infectious dermatitis: An underdiagnosed, unremitting and stubborn condition

Elena Daniela Serban

Elena Daniela Serban, 2nd Department of Pediatrics, “Iuliu Hatieganu” University of Medicine and Pharmacy, Emergency Hospital for Children, Cluj-Napoca 400177, Romania

ORCID number: Elena Daniela Serban (0000-0003-0906-1232).

Author contributions: Serban ED contributed to the paper’s conception and design, the data collection, extraction, analysis and evaluation, the interpretation of results, and the manuscript’s preparation, critical revision, editing and final submission.

Conflict-of-interest statement: The author declares there are no potential conflicts of interest relevant to this publication.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Correspondence to: Elena Daniela Serban, MD, PhD, Associate Professor, Pediatric Gastroenterologist, 2nd Department of Pediatrics, “Iuliu Hatieganu” University of Medicine and Pharmacy, Emergency Hospital for Children, 5 Crisan Street, Cluj-Napoca 400177, Romania. daniela.serban@umfcluj.ro
Telephone: +40-264-532216
Fax: +40-264-590478

Received: June 24, 2018
Peer-review started: June 25, 2018
First decision: August 2, 2018
Revised: August 23, 2018
Accepted: October 8, 2018
Article in press: October 9, 2018
Published online: October 25, 2018

Abstract

Perianal infectious dermatitis (PID) represents a superficial inflammation of the perianal skin, which is of bacterial origin (classically, group A beta-hemolytic streptococci). This narrative review aims to critically review and summarize the available scientific literature regarding pediatric PID, being the first of its kind, to the best of the author’s knowledge. It also reports the first cases of Romanian children with PID. Multiple databases were subjected to systematic literature search (from 1966 to April 30, 2018) to identify studies and case reports of children with PID. As such, this review provides updated information about essential aspects of PID (epidemiology, etiology, pathogenesis, as well as clinical features, required investigations and therapeutic options) and of diagnostic pitfalls. Although a well-defined entity, PID remains largely underdiagnosed. PID may mimic other common conditions with skin manifestations (like candidiasis, pinworms, eczema, irritant dermatitis, anal fissure, hemorrhoids, Crohn’s disease, psoriasis, seborrheic dermatitis, zinc deficiency dermatosis and even sexual abuse), with consequent unnecessary, sometimes expensive and invasive investigations and futile therapies, which cause patients and families discomfort and distress. Since PID has an unremitting course, early recognition is imperative, as it allows for prompt and efficacious antibiotic therapy. However, PID represents a stubborn condition and, even if properly treated, its recurrence rate remains high. Further well-designed prospective randomized controlled trials, with adequate follow-up, are required in order to formulate the optimum personalized antibiotic therapy (oral alone or in association with topical medication), able to prevent recurrences. Awareness of this condition by healthcare professionals should improve patient outcomes.

Key words: Perianal dermatitis; Perianal streptococcal dermatitis; Beta-hemolytic streptococci; Staphylococcus aureus; Perineal streptococcal dermatitis; Perianal swab culture; Differential diagnosis; Antibiotic therapy; Perianal streptococcal disease

© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: Perianal infectious dermatitis (PID) represents a superficial inflammation of the perianal skin, which is of bacterial origin. This narrative review aims to summarize the available literature regarding pediatric PID, being the first of its kind, to the best of the author's knowledge. An updated insight into the main features of PID is provided, including diagnostic pitfalls. PID may mimic other common conditions with skin manifestations, with consequent application of a treatment that is wrong. The unremitting course of PID makes early recognition and antibiotic therapy crucial. Recurrence rates of PID remain high. Awareness of this condition should improve patient outcomes.

Serban ED. Perianal infectious dermatitis: An underdiagnosed, unremitting and stubborn condition. World J Clin Pediatr 2018; 7(4): 89-104 Available from: URL: http://www.wjgnet.com/2219-2808/full/v7/i4/89.htm DOI: http://dx.doi.org/10.5409/wjcp.v7.i4.89

INTRODUCTION

Perianal infectious dermatitis (PID) represents a superficial inflammation of the perianal skin, which is of bacterial origin[1]. The first cases of pediatric PID, all caused by group A beta-hemolytic streptococci (GAS), were published more than 50 years ago[2]. Still today, the clinical hallmark of PID is represented by a characteristic well-demarcated perianal edematous erythema, extending 2-4 cm around the anus[1-10], sometimes with white exudate, pseudo-membranes and superficial anal fissures or cracks[1,10-12]. Despite its typical features, PID is still unrecognized by many healthcare professionals[13], as a result, patients are submitted to unnecessary investigations, sometimes invasive and costly (i.e., upper and lower digestive endoscopies under general anesthesia, and magnetic resonance enterography), as well as to various therapies. Delays in diagnosis and treatment increase patient discomfort and stress, which can also affect the patient’s family.

The aim of this narrative review, therefore, is to summarize the currently available scientific literature regarding pediatric PID as an alert to the medical community, to help ensure more instances of correct management. The author provides updated knowledge of essential aspects of PID (epidemiology, etiology, pathogenesis, as well as clinical characteristics, investigations required and therapeutic options) and of diagnostic pitfalls.

LITERATURE SEARCH

Published full manuscripts and abstracts were identified by a systematic literature search up to the date of April 30, 2018 for MEDLINE (PubMed), Web of Science and Mendeley (starting from 1966), EMBASE (starting from 1974), The Cochrane Library (starting from 1992), Google Scholar (starting from 2004), and Research Gate (starting from 2008) databases. Titles, abstracts and full-texts were searched without any language restriction. The reference lists from the selected studies were manually examined to identify additional research studies. Duplicates were excluded. The search included the following items/key words: “perianal cellulitis”, “perianal dermatitis”, “perianal disease”, “perianal infection”, “perineal dermatitis”, “perianal streptococcal cellulitis”, “perianal streptococcal infection”, “perianal streptococcal dermatitis”, “perianal streptococcal disease”, “perineal streptococcal disease”, “perineal streptococcal dermatitis”, “anitis”, and “anusitis”.

Only papers clearly presenting PID (as case reports, case series/observational studies or randomized controlled trials (RCTs)) and focused on children were retained for detailed analysis.

Data extraction

The following data were extracted: Last name of the first author; publication year; country; authors’ field of medical practice and working department; study design; characteristics of the included population (i.e., sample size, age, sex); symptoms and signs; etiology of the PID; presence or absence of pharyngitis or other site infections; results of throat culture and other relevant laboratory investigations; duration until diagnosis; important data concerning infections in family/community; previous investigations, diagnoses and therapies; type and duration of medication used to cure the PID; presence and rate of recurrence; medication used for recurrences; potential limits of the studies; and, any other relevant data regarding PID.

Characteristics of included studies

Sixty-four full-text articles reporting on pediatric cases of PID were included, being available from either the mentioned databases or (for older papers) by personally contacting their authors (email and/or phone). Only one reported on a RCT[12] (including 35 children); the remaining represented descriptive observational prospective studies/case series [6 articles, comprising a total of 351 patients (between 10 and 150/study)][2,6,11,14-16], descriptive observational retrospective studies/case series [16 articles, comprising a total of 549 patients (between 6 and 157/study)][4,5,8,10,17-28], and case reports [41, comprising a total of 75 patients (between 1 and 4 cases/report)][3,7,9,13,29-65]. Three cases diagnosed by this author were also added, giving a total of 78 case reports that were analyzed in this review. Ultimately, the analysis in this review involved the 78 patients from the case reports, 35 from RCTs, 549 from retrospective studies and 351 from prospective studies, giving a total number of PID pediatric cases of 1013.

The main characteristics of the included studies/case series are presented in Tables 1 and 2, and of the case reports in Tables 3 and 4. Four cases presented as case reports did not have the full-text manuscript available in electronic form[35,48,64], however, they are described in Tables 3 and 4, and are included in the total number of
either typical erythema or at least 2 of: perianal itching, constipation, anal pruritus, red or white discharge, anal fissure, pain, mucoid or bloody anal discharge; 1 F also with vulvo-vaginitis.

GAS: generalised anaerobic streptococcus.

Table 1: Studies/case series with perianal infectious dermatitis: Clinical and bacteriological patient characteristics

| Name, yr, country, study design | Population size; age; sex | Symptoms/signs1; symptom duration | Etiology of PID | Other findings2 |
|---------------------------------|--------------------------|----------------------------------|----------------|----------------|
| Amren, 1966, United States, PS[2] | 10; 1-8 yr, half < 5 yr; 90% M | Painful defecation, constipation, anal pruritus, perianal pain, mucoid or bloody anal discharge; 1 F also with vulvo-vaginitis | GAS (culture) | Throat GAS positive: 28% (no symptoms) |
| Spear, 1985, United States, RS[21] | 14; mean age 3.9 yr (1-10 yr); 11 M | Painful defecation (14), constipation (6), bloody stool (7), anal fissure (9); mean duration: 6.2 mo (range: 1-12 mo) | GAS (culture) | |
| Koks, 1987, United States, RS[21] | 31; 7 mo to 8 yr (mean 4.25 ± 1.8 yr); 77% M | Perianal itching (78%), rectal pain (52%), and blood-streaked stool (35%) | GAS and RADT | Throat GAS positive: 64%; identical perianal and pharyngeal T-type (T28, 5 cases; T4, 2; T2, 1) |
| Krol, 1990, Canada, RS[21] | 8; 8 mo to 10 yr; 6 M | Perianal pruritus (8); painful defecation (4); anal fissure (2); bloody stool (1); 3 wk to 6 mo | GAS (culture) | |
| Grant, 1993, United Kingdom, RS[21] | 20; 5 mo to 12 yr (mean 5 yr); 75% M | Perianal discomfort (14) and itch (13), fresh blood per rectum (12), pain on defecation (10), perianal pain (4), anal mucus discharge (2); 3 wk to 1 yr (mean 3 mo) | GAS (culture) | |
| Patrizi, 1994, Italy, RS[21] | 1. 10 yr, M | 1. Pruritus, tenesmus, constipation, acute GP and mild balanitis | GAS (culture) | 1. Throat GAS negative; penile GAS: same antibiogram |
| | 2. 4 yr, F | 2. Anal pruritus, vulvar and perineal erythema, and GP; 4 mo | | 2. Throat GAS negative |
| | 3. 5 yr, F | 3. PID and GP | | 3. Throat GAS positive |
| | 4. 9 yr, M | 4. Painful defecation, GP; 1 mo | | 4. Throat GAS positive |
| | 5. 7 yr, M | 5. PID and balanitis | | 5. GAS tonsillitis 3 mo before; penile GAS and mother with cervical GAS (child and mother bathing together) |
| Wright, Australia, 1994, PS[21] | 22; 5 mo to 8 yr (mean 41 mo); 13 M | Painful defecation, bleeding ± anal pain, perianal pruritus, constipation | Culture: 12 GAS, 1 GBS; 1 CDS | Throat GAS positive: 92% (± symptoms) |
| Mostafa, 1997, Egypt, PS[21] | 150; 2 mo to 11 yr (mean 3.8 ± 2.1 yr); 75% M | Perianal itching (15%), gastroenteritis (34%) | BHS: 35.3%, S. aureus 3.4% | Throat: BHS 44% (GAS 21.3%, non-GAS 22.7%); PID caused by GAS: 53.8% with same GAS in the throat |
| Barzilai, 1998, Israel, PS[21] | 18; 7 mo to 54 yr; 10 M | Perianal pruritus (50%); painful defecation or constipation (44%); anal fissure (39%); purulent secretion (27%); rectal bleeding (16%); 2 GP | GAS | GAS in other locations: 72%; 4 siblings throat GAS positive (no symptoms) |
| Mogielnicki, 2000, United States, RS[21] | 23; mean age 5 yr (1-11 yr); 13 F | 13 only PID; 2 PID + vulvo-vaginitis; 8 only vulvo-vaginitis | GAS (culture) | Throat GAS positive: 92% (± symptoms) |
| Mateo, 2002, Spain, RS[21] | 10; 9 mo to 7 yr; 6 M | Oozing and rectal bleeding, anal pruritus, pain on defecation; 1 M also GP; 20 d to 2 yr | GAS | Throat GAS positive: 3/6 |
| Petersen, 2003, Denmark, RS[21] | 17; mean age 6 yr (3-13 yr); 7 M | Painful defecation, fresh blood on stool | GAS | Throat GAS positive 12%; 6/12 with T28 from kindergarten |
| Landolt, 2005, Switzerland, RS[21] | 13; 7 F | Obstipation (58%), painful defecation (50%), perianal itching (25%), melena (25%); 10 cases with > 1 symptom | GAS | |
| Echeverria Fernandez, 2006, Spain, PS[21] | 19; 6 mo to 4 yr (median age 12 mo); 35; 1-16 yr | Anal pruritus (19), constipation (9), anal fissures (5), rectal bleeding (4), vulvo-vaginitis (2) | GAS (RADT and culture) | Throat GAS positive: 80%; GAS pharyngitis: 1 case |
| Meurly, 2008, Switzerland, RCT[21] | 65; 16 yr (median age 12 mo) | Either typical erythema or at least 2 of: perianal itching, rectal pain, painful defecation, constipation, blood-streaked stool, mucopurulent discharge, or anal fissure | GAS | |
| Jongen, 2008, Germany, RS[21] | 21; < 14 yr (mean age 6.3 yr); 76% M | Perianal itching, sore anus, bleeding and pain at defecation; mean duration of 6.6 months (2 wk to 2 yr) | 17 GAS, 4 GBS | GAS (RADT) |
| Shouval, 2008, Israel, RS[21] | 11; 6 mo to 4 yr (mean 24 mo); 73% M | Irritability (all), perianal itching (6) and pain (3); < 28 d | GAS (RADT) | |
| Heath, 2009, United States, RS[21] | 26; 5 mo to 12 yr; 15 F | Anal erythema or recurrent buttocks dermatitis; in PID caused by S. aureus: specific small papules and pustules of the buttocks or extension of the erythema to adjacent buttock skin | S. aureus 82%, GAS, GBS | |
| Olson, 2011, United States, RS[21] | 81; mean age, M: 4.1 yr and F: 4.6 yr; 58% M | Perianal involvement; (22.2%) symptoms for at least 2 wk (6.2% with symptoms for at least 4 wk); the rest: duration > 1 wk | GAS | |
| Clegg, 2015, United States, RS[21] | 157; 18 d to 12.5 yr, mean 4.8 yr, 53% M | Predominant site of involvement: M: perianal (86%) and F: perivaginal area (62%); 9.8 d | GAS | Throat GAS positive: 95%; 100% concordance between perianal and pharyngeal GAS |
patients analyzed, and provided epidemiological, clinical and bacteriological data. Five papers found as references in other reports could not be included, as their abstracts and full-text manuscripts were not available in electronic format and there was also no reply to this author’s inquiry, initially made in December 2016[66-70]. Table 5 presents previous investigations, diagnoses and therapies in children finally diagnosed with PID.

DEFINITIONS AND TERMS USED

Initially, the PID condition was described as “perianal cellulitis” in 1996 by Amren et al[2], this term has since been used by other authors[10,14,28-31,38,56,59,61,63]. However, the term “cellulitis” was later considered inaccurate, since inflammation involves only the skin[4,20]. The more appropriate term of “perianal streptococcal dermatitis” was introduced by Krof[20] in 1990 and used both in pediatric[8,9,11,13,17,19,20,22,24,34-36,39-47,49,51-53,55] and adult cases[71-75]. The terms “anitis”[13,55] and “anusitis”[67] were also used, but only in a few papers. Other authors preferred to name this condition “perianal streptococcal infection”[7,11,16,18,27,33,37,50,60,65,70,77] or “perianal streptococcal disease”, as introduced in 1987 by Kokx et al[4,64,4,78]. Mogielnicki et al[10] introduced the term “perianal streptococcal disease”, as the infection may extend to genital organs. Others preferred “perianal streptococcal infection”[23] or “perianal streptococcal dermatitis”[4,5,26,79].

Recently, the proposed term is “PID”[41], as other infectious bacterial agents have also been proven to cause this condition[3,8,24,36,32,58].

EPIDEMIOLOGY

The incidence of pediatric PID is unknown. With so many terms used for the same condition, it is not surprising that its frequency is not determined. However, the main reason for this unknown incidence is considered the fact that PID remains too often unrecognized by healthcare professionals. PID appears all over the world and has been reported by authors in various countries from different continents, including the United States[2,4,5,23,25,26,28,32,38,43,46,57,59,61-63], Canada[3,20,40], Australia[11,33], Africa (Egypt[15]), Europe (United Kingdom[7,10,29,30,65], Spain[16,19,21,31,42,64], Italy[2,4,8,10,29,47,48], The Netherlands[26,60], Finland[37], Sweden[41,50], Germany[8,9,45], Denmark[27], Switzerland[12,17,54], France[3,16,55], Greece[38], Asia (India[44], Taiwan[49], Japan[51,52], Iran[56], Israel[14,18] and Turkey[53]).

It appears that no cases have been published from Eastern Europe.

Considering incidence of PID caused by GAS among all pediatric consultations in different services, rates have varied from 1 case/2000 patients (May 1964 through July 1965 in a pediatric department in the United States[2]) and in a study published in 2015 from another pediatric center in the United States[23]) to 1 case/400 outpatient visits (January through March 1990 in a pediatric hospital in the United States)[90], 1 case/218 patients (October 1985 through June 1986 in a pediatric hospital in the United States)[51], 1 case/200 patients (October 1990 through May 2001 in a pediatric clinic in Switzerland)[17]. As seen, most data have originated from the United States, with only one report being from Europe. The only other European paper reporting frequency of PID was a German case series, albeit from a colorectal surgery clinic. PID was detected in 16% of patients aged a maximum of 14 year with ano-rectal complaints, from February 2003 through September 2006[8]. In a rural area of Denmark, the annual incidence was determined to be 2-7 in 1000 children[23]. From a survey performed among general practitioners in 1996 in an urban area of the United Kingdom, it was concluded that PID might be seen, on average, once or twice a year. Lack of awareness was considered the main reason for PID being missed in primary care[27].

Regarding age, PID is particularly encountered in children, especially between the ages of 6 mo and 10 years[2-4,6,11,20,22,28], with a maximum incidence peak between 3 years and 6 years[24]. However, cases have been described in infants less than 6 mo of age[15,23,26,43,57] or older than 10 years[5,10,15,23,26,27,39,48,62], and even in adults[52,61,71-78,81-84].

Boys have been initially described as predominantly affected by PID, representing about or more than 70%-80% of cases[2,4,8,10,15,18,20,21,28] (Table 1). Also, most
Table 2  Studies/case series with perianal infectious dermatitis: Therapy and follow-up of patients

| Name, yr, country | Therapy of PID and results | Follow-up of PID |
|-------------------|-----------------------------|------------------|
| Ameren, 1966, United States[5] | IM Pen, 10 d plus oral Pen, 10 d: disappearance of symptoms in 2-3 d | After therapy: 2 cases GAS positive; 10 d of Pen (same type): Effective in eradicating GAS in both cases |
| Spear, 1985, United States[6] | Oral Pen: rapid resolution of PID | Recurrence of infection: Not uncommon, requiring a repeated course of oral AB |
| Koks, 1987, United States[7] | Oral Pen or amoxicillin, 10 d: clinical and bacteriological clearance in 61% | 39% relapses, treated with IM or oral Pen; 4 children failed; 3 successfully treated with oral clindamycin, 10 d; 4^rd case successfully treated with oral Pen (10 d) and rifampin (last 4 d) |
| Kroll, 1990, Canada[8] | Oral Pen, 10 d plus topical mupirocin in 4 cases (these 4 without recurrence) | 2 cases: 2^nd course of therapy within 1 mo |
| Grant, 1993, United Kingdom[9] | Oral Pen, 3 wk: 14 responded (6 plus topical fucidin) | 6 cases: No complete response; successful 2^nd course of oral Pen and topical fucidin |
| Patrizi, 1994, Italy[10] | 1. Oral erythromycin, 14 d 2. Oral Pen, 2 wk 3. Oral erythromycin, 2 wk 4. Oral erythromycin and topical mupirocin, 2 wk 5. Amoxicillin, 2 wk: good results | 1. 4 wk later, GP and PID disappeared and all swabs negative 2. Lesions improved, but swab positive: erythromycin, 2 wk: complete healing (including negative GAS) 3. Lesions disappeared in maximum 5 wk 4. 4 wk later, lesions and culture negative 5. 4 wk later, perianal GAS, no lesions; 2^nd course of amoxicillin: good results |
| Wright, Australia, 1994[11] | Oral amoxicillin - clavulanate plus topical bacitracin, 2 wk | 50%: Response to treatment in 2 wk; no recurrence 1 wk after finishing first therapy |
| Barzilai, 1998, Israel[12] | Oral amoxicillin, 10 d and topical mupirocin: 16 patients clinically cured; perianal cultures GAS negative: days 3-5 of therapy and weeks 2 to 3 post-therapy | All with favorable response and no recurrence 3 cases: Clarithromycin, 7 d; no recurrence |
| Mateo, 2002, Spain[13] | IM Pen (1), oral amoxicillin (5), topical mupirocin (4) | 4 with persistent symptoms: 2^nd course of AB - oral Pen (3 cases), 14 d and oral clarithromycin (1 case), 10 d; 1 mo later: all 4 healed |
| Petersen, 2003, Denmark[14] | Oral Pen, 10 d: ineffective in 3 cases | Favorable in 85%, perianal GAS negative in 95% |
| Landolt, 2005, Switzerland[15] | 10 with > 1 symptom: oral Pen, 10 d; 3: oral or IV amoxicillin-clavulanate | Recurrence: 2 cases (clinical and culture); successfully retreated after 1 wk |
| Echeverría Fernández, 2006, Spain[16] | Oral Pen, 10 d | All with favorable response and no recurrence |
| Meury, 2008, Switzerland[17] | 15 cases: oral Pen, 10 d and 14 cases: oral cefuroxime, 7 d | Clinical improvement: More rapid in the cefuroxime group (P = 0.028) and perianal GAS negative the last day of therapy in 93% on cefuroxime vs 47% on Pen (P < 0.01) |
| Jongen, 2008, Germany[18] | Oral Pen + local polihexanid, 10-14 d | 1 case: New GAS associated PID 5 mo later; successfully treated with oral AB 1 wk after finishing first therapy |
| Shouval, 2008, Israel[19] | Oral amoxicillin, 10 d and topical mupirocin (8/11): complete healing in 73% | Recurrence: 3/11; 2^nd course of AB administered |
| Heath, 2009, United States[20] | Oral cephalexin for S. aureus: Successful in all but one; 4 cases with S. aureus cleared on topical mupirocin and 1 on bleach baths and topical steroids | 1 case with MRSA: 2^nd course of oral AB required |
| Olson, 2011, United States[21] | Oral AB alone: 81.4%; topical agent alone: 2.5%; both: 16%; duration: oral beta-lactams 10 d, azithromycin 5 d, cephalexin 5 d, oral Pen 14 d | Recurrence: 32.1%; recurrence within 6 wk 69.2%; recurrence rate: After Pen or amoxicillin 38.1% vs 27.8% after a beta-lactamase resistant AB (adjusted odds ratio: 2.02) |
| Clegg, 2015, United States[22] | Amoxicillin 82.2%; cephalexin 11%; other AB 7%; topical therapy: 6% | Recurrence rate (symptomatic PID) 6 mo after the initial episode: 13.4% after any AB, 12.4% after amoxicillin, 29.4% after cephalexin, and 0% after all other AB (oral Pen, amoxicillin-clavulanate, azithromycin, clindamycin, cefprozil and cefdinir) |
| Garcia, 2015, Spain[23] | Oral AB (Pen 5, amoxicillin 1), plus 4 topical mupirocin and 3 clotrimazole | All BHS: susceptible to Pen; all GAS susceptible to clindamycin, 1.4% resistant to erythromycin; GBS resistant to erythromycin in 14.8% and clindamycin in 7.4% of cases |
| Sterbenč, 2016, Slovenia[24] | | Satisfactory; 1 recurrence |

AB: Antibiotic; BHS: Beta-hemolytic streptococci; GAS: Group A beta-hemolytic streptococci; GBS: Group B beta-hemolytic streptococci; GP: Guttate psoriasis; IM: Intramuscular; IV: Intravenous; Pen: Penicillin; MRSA: Methicillin-resistant S. aureus; PID: Perianal infectious dermatitis.

case reports have presented male patients (Table 3). No precise reason has been found for this predominance; hormones and immune factors may contribute to it[52]. However, other series showed smaller rates of male predominance (53%)[13], 55.5%[14], 58%[15], 59%[16], 60%[17] and 64%[18], while four studies reported a slight female predominance (54%[17], 57%[15], 56%[18] and 63%[18]).

Concerning seasons, most cases of PID caused by GAS appeared in winter[19,20,21,22] and spring[13,14,23,24], when GAS infections of the upper respiratory tract are also more
The three siblings bathing together

**Table 3** Case reports with perianal infectious dermatitis: Clinical and bacteriological patient characteristics

| Name, yr, country | Case age, sex | Symptoms/signs; symptom duration | Etiology of PID | Other findings |
|-------------------|---------------|----------------------------------|----------------|---------------|
| Hirschfeld, 1970, United States | 1-2. 6 yr, F and 3 yr brother | 1-2. Painful defecation; several days | GAS (culture) | 1-2. Both had sore throats 2 wk prior |
| | 3-4. 5 yr and 3 yr brothers (unrelated family) | 3-4. Same history and symptoms | | |
| Farmer, 1987, United Kingdom | 1. 4 yr, M and 2.5 yr, F | 1. White anal discharge, perianal pustules; 3 wk GAS (culture) | | |
| | | 2. Perianal itching, pain on defecation, dysuria; vulva affected; 3 wk | | |
| Rehder, 1998, United States | 1. 3 yr, M and 2.3 yr, M | 1. Rectal irritation; 6 mo GAS (culture) | 1. Sibling, 6 yr: GAS pharyngitis recently discovered; 2. Patient: throat GAS positive; sibling with recent sore throat |
| | 3. 4 yr, M and 4.3 yr, F | 2. Perianal pain and itching; 5 wk GAS (culture) | | |
| | | 3. Perirectal pain; 6 wk | | |
| Horig, 1988, United States | 4; 15 mo, 6, 8 and 12 yr; 3 M | Anal pruritus, bloody anal discharge; GP: 2 cases, appeared 9 mo after onset of PID; 1 M with PID history of 2 yr | GAS (culture) | 3. Identical GAS from anus and throat |
| | | | | |
| Marks, 1988, United States | 5 yr, M | Perianal irritation and pruritus, bloody discharge; 2 wk GAS (culture) | | |
| | | | | |
| Guerrero - Vázquez, 1989, Spain | 2 cases | Perianal irritation in both; seropurulent anal and balano-preputial discharge in 1 case GAS (culture) | | |
| Dubra, 1990, United States | 5 yr, M | Painful defecation, micturition, bloody stool; penile erythema swelling; 4 wk GAS (culture) | | |
| Goodyear, 1991, United Kingdom | 4 yr, M | Painful defecation, blood-streaked liquid stool; fecal incontinence; 6 wk GAS (culture) | | |
| Medina, 1992, Spain | 4 yr, M | Perianal pruritus and bleeding; 3 mo GAS (culture) | | |
| Montemarano, 1993, United States | 3 yr, M | Painful perianal area, satellite pustules; 2 mo GAS (T28) | S. aureus positive in anterior nares and satellite pustule | |
| Guppy, 1993, Australia | 1.7 yr, M | 1. Perianal excoriation; 8 wk GAS (culture) | S. aureus | |
| | 2-3. His 2 brothers, 5 and 2.5 yr | 2-3. Similar history | | |
| | 4.4 yr, M and 3 yr, M | 4. Typical PID; penis lesions later; 4 wk GAS (culture) | | |
| | | | | |
| Paradisi, 1993, Italy | 1.3 yr, F and 2.5½ yr, M, brother | Painful defecation, perianal itching, rectal bleeding, constipation | GAS | |
| Paradisi, 1994, Italy | 4 yr, M | Constipation, painful defecation, diarrhea | GAS (culture) | Brothers shared same toilet |
| van Zeijl, 1996, Netherlands | 4; 3 M (1, 6 and 8 yr, the last 2 brothers); 1 F (2 yr) | Constipation, painful defecation, diarrhea | GAS (culture) | |
| | | | | |
| Sexen, 1997, Finland | 1.3 yr, M | 1. Itchy anus and bloody stool; 1 w GAS (T28) | 2. Throat GAS positive, identical (T28) | |
| | 2-3. Other cases | 2. Same symptoms Constipation, myositis GAS (culture) | His mother had sore throat GAS positive | |
| Berlin, 1997, United States | 3 yr, M | | | |
| Bugatti, 1998, Italy | 12 yr, M | Perianal discharge, 1 mo GAS (culture) | | |
| Adams, 1999, Canada | 1 yr, M | Typical PID GAS (culture) | | |
| Roos, 1999, Sweden | 5 yr, M | Anal pruritus GAS (T28) | Case: throat GAS negative; mother: GAS tonsillitis positive; anal and throat GAS identical | |
| Velez, 1999, Spain | 2 yr, M | Fever 39-40 ℃, erythema: perianal, genitalia and proximal thighs GAS (culture) | Throat negative | |
| Herbst, 2000, Germany | 4 yr, M | GP; 6 w history; PID discovered at physical exam GAS (culture) | Patient and family members: Negative GAS | |
| Brilliant, 2000, United States | 1.4 yr, M and 2.3. 2 mo and 30 mo | 1. Rectal itching and pain, scant mucoid discharge GAS (RADT + culture) | | |
| | | 2-3. Several days later with similar symptoms | | |
| Balasubramanian, 2000, India | 1. 13 mo, M and 2.11 mo, M and 3.13 mo, F | 1. Fever, painful defecation, anal pruritus; 2 d GAS (culture) | 2-3. Siblings of case 1 |
| | | 2-3. Fever, painful defecation | | |
| Heidelberger, Germany, 2007 | 1.6 yr, M and 2.9 yr, M | 1. Anal itching and burning; 3 mo GAS (culture) | 4. Neighbor of the 3 cases |
Table 2: Overview of PID cases in children from November 2009 to March 2010

| Author               | Age | Gender | Symptoms and Findings                                                                 | Diagnosis       | Culture Positive |
|----------------------|-----|--------|--------------------------------------------------------------------------------------|-----------------|------------------|
| Nowicki, 2009, US    | 7 yr | M      | Perianal itching, painful defecation; 10 d                                           | GAS (culture)   | Throat GAS positive |
| Souliet, 2009, France| 7 yr | F      | Vulvar erythema, perirectal pain, painful defecation, constipation; perioral impetigo; 3 wk | GAS (culture)   | Perioral GAS positive |
| Lungá, 2001, Italy   | 1. 4 yr, M | 1. Perianal discomfort; 2. 6 yr, M | 1. Perianal itching, painful defecation, scant mucoid discharge; 2. Purulent discharge plus balanitis | GAS (RADT) | 4 d later: Father with symptoms of PID and GAS positive, sore throat 2 wk before; no culture, no therapy needed |
| Huang, 2003, Taiwan  | 6 yr, M | 1. Throat culture negative; 2. Anal pruritus, painful defecation, anal mucous and bloody discharge | GAS (culture) | Throat GAS positive |
| Reimer, 2004, Sweden | 1. 4 yr, M | 1. Perianal discomfort; 2. 6 mo, M | 1. Perianal itching, painful defecation, scant mucoid discharge; 2. Throat culture negative; vulvar culture few | GAS (culture) | Throat GAS negative |
| Takeshita, 2006, Japan | 3. 4 yr, F | 3. Perianal pain, vulvar erythema and pain | 1. PID; 2 wk | 3. GAS |
| Usuki, 2004, Japan   | 1. 2 yr, F | 1. Throat culture negative; 2. Throat culture negative; vulvar culture few | 1. GAS (RADT) | GAS (culture) |
| Ulger, 2004, Turkey  | 3 yr, M | Pain on defecation, anal pruritus; 8 d; GP: 2 d | 1. Painful defecation, CP, penile erythema | GAS (culture) |
| Greisser, 2008, Swiss | 7 yr, M | Perianal pain and pruritus, yellow discharge; 3 d | 1. GAS (RADT) | GAS (culture) |
| Lehman, 2009, UK     | 3 yr, F | Itchy bottom and painful defecation; 2 wk | 1. GAS (RADT) | GAS (culture) |
| Ledoux, 2009, France | 4 yr, M | PID for 2 wk; lesions of GP since second week | 1. GAS (RADT) | GAS (culture) |
| Rasi, 2009, Iran     | 4 yr, M | Rectal itching and burning, pain on defecation; plaque type psoriasis; 3 mo | 1. GAS (RADT) | GAS (culture) |
| Block, 2013, US      | 1. 2 mo, F | 1. PID and vulvar erythema | 1. 8 yr sibling; previous GAS pharyngitis |
| Theotokatou, 2014, Greece | 1. 8 yr, M | 1. Perianal itching, constipation, blood-streaked stool; 3 wk | Enterooccus faecalis (culture) in both | GAS |
| Zhang, 2016, Canada  | 2. 10 yr, M, brother | 2. Perianal itching and mucous discharge (2 wk after onset of symptoms of his brother) | 1. GAS and S. aureus | 1. Throat GAS positive |
| Garritsen, 2017, Netherlands | 19 mo, M | PID and 1 wk later: GP | 1. GAS (culture) | 1. Throat GAS positive, GAS and S. aureus negative |
| Serban, present study, Romania | 1. 9 yr 4 mo, M | 1. Perianal pain and pruritus, anal mucous and bloody discharge, painful defecation; 6 wk | 1. GBS and S. aureus (culture) | 1. Throat GAS, GAS and S. aureus negative |
|                     | 2. 9 yr 6 mo, M | 2. Anal pruritus, painful defecation, anal mucous and bloody discharge | 2. GAS (culture) | 2. Throat GAS positive |
|                     | 3. 11 yr 9 mo, M | 3. Anal pruritus, mucous and bloody discharge, painful defecation, constipation | 3. GAS (culture) | 3. Throat GAS negative |

1Besides typical perianal erythema; 2 Especially throat culture and infections in the family/community. F: Female; GAS: Group A beta-hemolytic streptococci; GBS: Group B beta-hemolytic streptococci; GCS: Group C beta-hemolytic streptococci; GP: Guttate psoriasis; M: Male; PID: Perianal infectious dermatitis; RADT: Rapid antigen detection test; S. aureus: Staphylococcus aureus; T28: T-type 28 of GAS.

Prevalent. Only 30% of cases were reported in June and July in the initial paper by Amren et al[15], while the rest were during spring and winter. A recent prospective study found most cases in autumn (peak of 21% in November[16]), while a report published that same year[17] also had a maximum incidence in October and March (65% of cases[18]). Interestingly, PID caused by Group B streptococci (GBS) also had a maximum incidence during winter and spring[19].

Cases of PID in the same family and/or with interfamilial spread have been extensively documented, transmitted from children to parents[20] or vice versa[21,22,38,39] or between siblings[23,33,35,36,43,47,50,51,59] or other family members[26] or friends[45]. In the study by Kokx et al[41], among 31 children from 19 families, intrafamilial spread was detected only in siblings and occurred in 50% of the possible situations, with 7 families representing multiple cases of PID. Also, small epidemics (outbreaks) in daycare centers have been published[5,27,21]. In the study reported by Mogielnicki et al[5], of 23 cases, 10 had contact with someone with PID. Saxén et al[37] showed that a small outbreak of 3 culture-confirmed PID cases caused by GAS and 2 non-verified clinical PID cases occurred within 9 d in a group of 20 daycare children. The following risk factors for PID have been described: perianal skin lesions; poor hygiene; poor living conditions; overcrowded houses;
| Name, yr, country      | Case age, sex            | Therapy of PID and results                                               | Follow-up of PID                                      |
|------------------------|--------------------------|------------------------------------------------------------------------|------------------------------------------------------|
| Hirschfeld, 1970, USA   | 1-2. 6 yr, F and 3 yr brother | Oral Pen                                                              |                                                      |
| Farmer, 1987, UK        | 1. 4 yr, M               | 1. Oral Pen; prompt and complete recovery                              | 1. 2 wk later, erythema and GAS positive: erythromycin, for 1 mo; no recurrence (including culture) |
| Rehder, 1998, USA       | 1. 3 yr, M, F            | 1. Oral Pen, 2 wk                                                      | 2. No recurrence (including cultures)                |
|                        | 2. 3 yr, M               | 2. Oral Pen, 2 wk                                                      |                                                      |
|                        | 3. 4 yr, M               | 3. Oral Pen, 3 wk                                                      | 3. Perianal cultures positive after 2 and 3 wk: erythromycin, 10 d: negative culture |
|                        | 4. 1 yr, F               | 4. Oral Pen, 3 wk: both conditions cleared                            | 4. All negative                                      |
| Honig, 1988, USA        | 4; 15 mo, 6, 8 and 12 yr; 3 M | Oral Pen, 10 d; PID cleared in 3 cases within 10-14 d                | The 4th case with PID history of 2 Y: 10 d of erythromycin, cleared PID and negative culture; psoriasis cleared 14-35 d after institution of therapy |
| Marks, 1988, USA        | 5 yr, M                  | Oral Pen, 14 d; rash progressively healed (completely in 17 d)        | Other 2 wk of oral Pen cleared and GAS               |
| Duha, 1990, UK          | 5 yr, M                  | Oral Pen, 3 wk; clearance of penile lesion (2 wk), but not perianal, also with positive GAS | Follow up 2 mo later: clinically well                |
| Goodyear, 1991, UK      | 4 yr, M                  | Oral Pen, 10 d; completely resolved in 2 wk                           | Negative cultures 1 wk and 1 mo later               |
| Medina, 1992, Spain     | 4 Y, M                   | Topical mupirocin, 10 d: Completely resolved                          |                                                      |
| Montemarano, 1993, USA  | 3 Y, M                   | Oral erythromycin, 10 d: Rapid cure                                   |                                                      |
| Guppy, 1993, Australia  | 1. 7 yr, M               | 1. Oral Pen, 10 d                                                     | 1. After stopping Pen, rectal bleeding: Cefaclor, 10 d, no recurrence |
|                        | 2-3. His 2 brothers, 5 and 2.5 yr | 2. Oral Pen, 10 d                                                     | 2. No recurrence                                     |
|                        | 4. 4 yr, M               | 4. Oral Pen, 2 wk, incomplete resolution                              | 3. 3 mo later: Persistent perianal infection: erythromycin |
|                        | 3 yr, M                  | Topical erythromycin, 15 d: Complete clinical and bacteriologic resolution | No recurrence                                      |
| Paradisi M, 1993, Italy | 4; 3 M (1, 6 and 8 yr, the last 2 brothers); 1 F (2 yr) | Oral Pen, 10 d; mupirocin or fusidin |                                                      |
| van Zeijl, 1996, Netherland | 1. 3 yr, M            | Oral amoxicillin + fusidin                                            |                                                      |
| Saxen, 1997, Finland    | 1. 3 yr, M               | 1. Oral Pen, 10 d; clearance within 2 d                              | 1. 1 wk after stopping Pen: PID recurrence, with GAS positive; oral cephalesin: good results |
| Berlin, 1997, USA       | 3 yr, M                  | IV antibiotics (not mentioned)                                        | Symptoms resolved entirely after 2 wk                |
| Bugatti, 1998, Italy    | 12 yr, M                 | Amoxicillin, 10 d: Rapid resolution of symptoms                      |                                                      |
| Adams, 1999, Canada     | 1 yr, M                  | Oral Pen and topical mupirocin, 10 d                                  |                                                      |
| Roos, 1999, Sweden      | 5 yr, M                  | Cefadroxil plus topical fusidin, 10 d                                 | No recurrence                                        |
| Velez, 1999, Spain      | 2 yr, M                  | Cefaclor, 10 ds complete healing                                      | 2 wk after therapy: Acral (hands and feet) scarlatiniform desquamation |
| Herbst, 2000, Germany   | 4 yr, M                  | Oral Pen and topical fusidin, 2 wk: Complete healing (including culture) |                                                      |
| Brilliant, 2000, Germany | 1. 4 yr, M              | 1. Oral amoxicillin, dramatic improvement 1 d                        |                                                      |
| United States[40]       | 2.3. 2 mo and 30 mo      | 2.3. Same effective therapy                                          |                                                      |
| Balasubramanianan, 2001, India[40] | 4. 4 yr, F         | 4. Same effective therapy                                            |                                                      |
| Heidelberger, Germany, 2000[40] | 1. 13 mo, M         | Oral Pen, 10 d; symptoms clearance in 3 d                           |                                                      |
| Newicki, 2000, United States[40] | 2.11 mo, M        | 2. Same plus topical clioquinol; in both cases, all lesions disappeared |                                                      |
| Souliet, 2000, France   | 7 yr, M                  | Oral Pen: Symptoms and signs disappeared                              | 1 wk following Pen, peeling from his fingers tip (toes not involved) |
| Lunghi, 2001, Italy     | 7 yr, F                  | Amoxicillin, 10 d; perianal lesions cleared by day 2                 |                                                      |
|                        | Brother (4 yr) and sister (6 yr) | IM Pen, 4 wk, plus local mupirocin                                   | Complete resolution (with negative culture) within 4 wk; no relapse in 4 mo |
### Atopic dermatitis; chronic dialysis; and, malnutrition.

#### ETIOLOGY

The vast majority of cases in the pediatric literature are caused by GAS (Tables 1 and 3). It has been considered that the type T28 emm 28 of GAS (one of the most detected types causing PID) harbors unique properties, which may increase the likelihood of perineal infection. However, other agents have been reported 150 children with GAS, representing 21.3% and non-GAS 3.4% for S. aureus. In a retrospective 10-year study of patients with PID, 105 BHS were isolated from the perianal area of the same number of patients. GAS, GBS, GCS and GGS were cultured in 69.5%, 25.7%, 2.8% and 2%, respectively.

#### PATHOGENESIS

A few theories have been suggested for the infection of the perianal area, especially for GAS. They include spread by hand contact with the oral cavity and then perianal area, deglutition of GAS with dissemination along the gastrointestinal tract, contaminated fomites (communal bathtubs or toilets), and airborne spread. GAS are not considered part of the perianal skin flora and asymptomatic carriage is exceedingly rare. Digital oral-anal contact is a well-documented route.

### Table: PID: Underdiagnosed and unremitting

| Author, Year, Country | Age, Gender | Initial Treatment | Duration | Outcome |
|-----------------------|-------------|------------------|----------|---------|
| Huang, 2003, Taiwan   | 6 yr, M     | Oral Pen and topical mupirocin, 14 d: clinical healing after 4 d | After starting Pen: desquamation of fingers and perianal skin |
| Reimer, 2004, Sweden  | 1.4 yr, M   | Oral Pen in all cases: quickly healed | No recurrence |
| Greiseneder, 2008, Switzerland | 1.8 yr, M | Oral Pen | No recurrence |
| Garritsden, 2017, Netherlands | 1.4 yr, M | Oral Pen plus mometasone for GP | No recurrence in both cases |
| Serban, present study, Romania | 19 mo, M | Oral Pen plus mometasone for GP: 4 wk; PID and GP significantly improved | No improvement of psoriatic lesions |
| Rasi, 2009, Iran      | 4 yr, M     | Oral amoxicillin, 10 d: Clinical response within 3 d, healed in 3 wk; GAS negative after 3 wk | No recurrence of perineal involvement |
| Block, 2013, United States | 2.4 yr, F | Oral cefuroxime and topical mupirocin for both brothers: effective by day 4 | No recurrence of perineal involvement |
| Zhang, 2016, Canada   | 1.4 yr, M   | 1. Oral cefuroxime, 7 d plus topical fusidin | No recurrence of perineal involvement |
| Theotokatou, 2014, Greece | 2.10 yr, M, brother | 1. Oral cefuroxime, 7 d plus topical fusidin | No recurrence of perineal involvement |
| | 2. 4 yr, M | 2. Oral cefuroxime, 7 d plus betamethasone for GP | No recurrence of perineal involvement |
| | 3. 3 yr, F | 3. Oral cefuroxime, 7 d plus topical fusidin; persistent erythema and discharge | 3. Vulvar culture: GCS and GBS, perianal culture: GCS, culture from vaginal introitus: positive GAS: oral amoxicillin, 10 d |
| | 1. 9 yr 4 mo, M | 1. Spiramycin and topical mupirocin, 2 wk: improvement after 2 d; perianal culture negative on day 7; completely healed after 12 d | 1. No recurrence after 2 yr |
| | 2. 9 yr 6 mo, M | 2. Spiramycin, 2 wk: improvement since day 2; negative perianal culture on day 7; completely healed after 1 wk | 2. No recurrence after 7 mo |
| | 3. 11 yr 9 mo, M | 3. Spiramycin and topical bacitracin plus neomycin, 3 wk: improvement after 5 d; negative perianal culture on day 7; healed completely after 2 wk | 3. No recurrence after 2 mo |

F: Female; GAS: Group A beta-hemolytic streptococci; GBS: Group B beta-hemolytic streptococci; GCS: Group C beta-hemolytic streptococci; GP: Guttate psoriasis; IM: Intramuscular; IV: Intravenous; M: Male; Pen: Penicillin; PID: Perianal infectious dermatitis.
### Table 5  Previous investigations, diagnoses and therapies in children with perianal infectious dermatitis

| Name, yr, country | Population size; age; sex | Previous performed investigations and/or suspected diagnosis | Previous therapy |
|-------------------|---------------------------|-------------------------------------------------------------|-------------------|
| Spear, 1985, United States | 14; mean age 3.9 yr (range: 1-10 yr); M/F: 3.7/1 | 2 proctoscopies under general anesthesia, upper gastrointestinal x-ray series, barium enema; anal fissure, IBID, behavior disturbance, psychogenic stool holding, psoriasis, candidiasis, ammoniacal diaper dermatitis | Laxatives, suppositories, hydrocortisone, polymyxin, bacitracin and neomycin, povidone-iodine, triamcinolone |
| Farmer, 1987, United Kingdom | 1. 4 yr, M | 1. Anal pinworms (negative) | 1. Piperazine, miconazole, and hydrocortisone cream |
| Koks, 1987, United States | 31; 7 mo to 8 yr, mean 4.25 ± 1.8 yr; M 77% | Hemorrhoids, poor hygiene, perianal allergy to toilet paper perfumes, rectal fissures, and/or constipation | 2. Clotrimazole cream |
| Rehder, 1998, United States | 1. 3 yr, M | 2 proctoscopies under general anesthesia, upper gastrointestinal x-ray series, barium enema; anal fissure, IBD, behavior disturbance, psychogenic stool holding, psoriasis, candidiasis, ammoniacal diaper dermatitis | 1. Soaks, topical antifungals and corticosteroids |
| Marks, 1988, United States | 5 yr, M | Pinworms and stool for ova and parasites: negative | 2. Topical hydrocortisone, nystatin, triamcinolone and zinc oxide |
| Duha, 1990, United Kingdom | 5 yr, M | Considered as possible case of sexual abuse; threadworms, candidiasis, psoriasis and eczema | 3. Oral cefaclor, with clearing of erythema, but recurrence |
| Goodyear, 1991, United Kingdom | 4 yr, M | Examination under anesthesia and proctoscopy | Topical A and D ointment, hydrocortisone, ketoconazole |
| Montemarano, 1993, United States | 3 yr, M | | 3. Topical and oral nystatin |
| Grant, 1993, United Kingdom | 20; 5 mo to 12 yr; 75% | 2 cases: suspected Crohn’s disease; 1 case: suspected sexual abuse | Topical A and D ointment, hydrocortisone, ketoconazole |
| Guuppy, 1993, Australia | 1. 7 yr, M | 2-3. 5 and 2.5 yr | 1. Soaks, topical antifungals and corticosteroids |
| Adams, 1999, Canada | 1 yr, M | 4. 4 yr, M | 2. Topical hydrocortisone, nystatin, triamcinolone and zinc oxide |
| Roos, 1999, Sweden | 5 yr, M | 2 cases: suspected Crohn’s disease; 1 case: suspected sexual abuse | 3. Oral cefaclor, with clearing of erythema, but recurrence |
| Herbst, 2000, Germany | 4 yr, M | | Topical agents, including steroid cream |
| Brilliant, 2000, United States | 1. 4 yr, M | | Various ointments for the last several months |
| Patrizi, 1994, Italy | 5; 4-10 yr; 3 M | | 1. Topical tannolact seat baths and topical clotrimazole |
| Bugatti, 1998, Italy | 12 yr, M | | 2. Various antifungal, antibacterial and steroid creams, oral pyrantel embonate |
| Adams, 1999, Canada | 1 yr, M | | 3. Various antifungal, antibacterial and steroid creams, oral pyrantel embonate |
| Reoos, 1999, Sweden | 5 yr, M | | 4. Local nystatin, hydrocortisone; oral pyrantel embonate |
| Herbst, 2000, Germany | 4 yr, M | | Topical agents, including steroid cream |
| Herbst, 2000, Germany | 1. 6 yr, M | | Topical antifungal agents |
| Herbst, 2000, Germany | 2.9 yr, M | | 2. Topical corticosteroids and clotrimazole |
| Soulliet, 2000, France | 7 yr, F | | Nystatin unsuccessful for suspected candidiasis |
| Lunghi, 2001, Italy | Brother (4 yr) and sister (6 yr) | | Both: Local and oral antifungal drugs for 4 mo |
| Mateo, 2002, Spain | 10; 9 mo to 7 yr; 6 M | | 4 cases: 2 steroids cream, 1 clotrimazole cream and 1 betamethasone and clotrimazole cream |
| Reimer, 2004, Sweden | 1. 4 yr, M | 1. Pinworms (negative) | Topical agents (zinc paste, corticosteroids, antimycotic ointments) |
| Jongen, 2008, Germany | 3. 4 yr, F | | 3. Local ointment (keracutan) |
| Rasi, 2009, Iran | 21; < 14 yr (mean age 6.3 yr), 76% M | Anoscopy and rectoscopy: negative | Topical antibiotics, steroids and antifungal creams, 3 mo |
| Zhang, 2016, Canada | 1. 4 yr, M | | 1. Topical terbinafine and hydrocortisone acetate |
| Garritsen, 2017, Netherlands | 19 mo, M | | 2. Gentle skin care, zinc barrier cream, topical antifungals, corticosteroids, and mupirocin |
| Zhang, 2016, Canada | 3. 3 yr, F | | 3. Gentle skin care, zinc barrier cream, topical antifungals, corticosteroids, and mupirocin |
| Garritsen, 2017, Netherlands | 19 mo, M | | 4. Local nystatin, hydrocortisone; oral pyrantel embonate |

Serban ED. PID: Underdiagnosed and unremitting
Serban ED. PID: Underdiagnosed and unremitting

Serban ED. PID: Underdiagnosed and unremitting

|   |   |   |   |
|---|---|---|---|
| 1. 9 yr 4 mo, M | 1. Psoriasis, pinworms, candidiasis, eczema; Hospitalization in 6 public clinics and 2 private hospitals; upper and lower endoscopy under general anesthesia; magnetic resonance enterography - all negative; considered as Crohn’s disease and sent to our clinic |
| 2. 9 yr 6 mo, M | 2. Pinworms, intestinal dysbiosis |
| 3. 11 yr 9 mo, M | 3. Eczema, anal fissure, constipation |

F: Female; IBD: Inflammatory bowel disease; M: Male.

Figure 1 Perianal infectious dermatitis. A, B, C: Well-demarcated perianal erythema. B, C: With white exudate. Personal cases from the author (Elena Daniela Serban).

seriously diagnosed with GAS pharyngitis (siblings[57,61], mother[38,41] or father[50]). Self-inoculation has been reported in studies showing positive throat culture for GAS when PID was diagnosed. The rates of isolation of GAS from the throat of these children (with or without concomitant pharyngitis) have varied from 28%[2] to 38%[14], 50%[19], 53.8%[15], 64%[5], 80%[16], 92%[3] and 95%[23]. The high pharyngeal carrier frequency found in the studies by Mogielnicki et al[5] and Clegg et al[3] was considered very suggestive for PID, leading to a quick diagnosis (only 9.8 d)[23]. Also, case reports showed the same finding - concomitant positive throat culture for GAS[3,13,22,37,49,59,61] and 1 case from this author and presence of S. aureus in the anterior nares[52].

Eradication from pharynx could be more rapid than from the perineal area, explaining the various frequencies[5]. Conversely, only 6% of children with GAS pharyngitis are anal carriers of GAS[37]. In one study, the T-types of the pharyngeal and perianal GAS were identical[5]. Other authors also showed that the same perianal GAS was found in the throat[15,23,37,61]. Mostafa et al[15] reported 3.4% of PID caused by S. aureus, with the same bacteria in the throat in 2.7% of cases.

Children may infest the perianal skin also while using a shared toilet (sitting on it or cleaning the area after touching toilet, without washing hands) and/or communal baths[14,22,23,36], facts that could also explain the intrafamilial or interfamilial spread[1,27,37]. During the outbreak in a daycare center, the transmission route was reported to be most likely the common toilet and especially its GAS-contaminated plastic toilet seat[27].

Also, it had previously been suggested that oral bacteria can pass intact into the digestive tract and colonize the anus; however, this hypothesis is not accepted anymore[56].

CLINICAL PRESENTATION

Specifically, symptoms appear in otherwise healthy children, without fever, malaise or other systemic symptoms[1,13,43]. Symptoms like anal pruritus (itching), painful defecation with consequent retentive constipation, anal pain, mucous (sometimes purulent)[12,14] and/or bloody anal discharge (blood-streaked stools) are usually present[2,4-8,10,28,43,59]. Very rarely, abdominal pain (related to defecation or to retention to defecation)[21], fecal incontinence[2,21,30] or tenesmus[21-23] could be associated. Exceptionally, other symptoms have been reported, including fever[21,44], irritability[18], diarrhea[15,36] and muscular pain[38]. Synthetizing data from the literature (Tables 1 and 3), the following frequencies of symptoms and signs are detected: perianal itching (78%-100%); painful defecation (50%); constipation (47%-58%); blood-streaked stools (21%-60%); purulent secretion (27%); anal fissures (26%-40%); perianal pain (20%); and, mucous discharge at the anal margin (10%) [4-8,10,11,14,17,20,21].

The hallmark of PID (found in all included cases) is represented by the aspect of the perianal area - superficial, intense edematous vivid red erythema (like "raw beef"), rarely pink, sharply demarcated, extending 2-4 cm around the anus[1-10]. The area is sometimes extremely tender, rendering physical examination very difficult. White exudate, pseudomembranes and superficial anal fissures or cracks could also be detected[1,10-12]. Three cases of PID from this author’s experience are illustrated in Figure 1. The typical appearance could change, however, after applying various topical creams, rendering the diagnosis more difficult.

Infection can extend to genital organs, resulting in vulvo-vaginitis[2,3,5,6,13,16,21-23,43,47,50,57,65] or balanitis[3,22,23,29,33,42,45,50,64] and cultures from these areas grow same type of bacteria[2,22,28]. Small papules or pustules on the buttocks are suggestive for S. aureus[26,32]. Sometimes, extraperineal rash (mostly papulo-pustular or impetiginous) could also be associated, up to 35.8% in a recent series[25]. Another cutaneous finding, acral
desquamation (following therapy for PID caused by GAS and concomitant with resolution of PID) was reported by three authors; these included fingers, toes, and perioral skin. The presence of acral desquamation has been suggested to be the effect of streptococcal exotoxin. Rarely, when PID is diagnosed early, concomitant pharyngitis may be found.

INVESTIGATIONS
Simple methods are required to diagnose PID (Tables 1 and 3). Culture of anal, perianal, and perineal swabs represent the best option for diagnosis. Physicians should specifically ask for BHs culture, on blood agar plates, as laboratories do not adequately search for them in the evaluation of routine perianal swabs. Culture allows detection of the bacteria causing PID, besides GAS (including non-GAS, S. aureus, and E. faecalis). Moreover, it allows identification of their sensitivity to antibiotics, given that antibiotic resistance has become a seriously increasing issue across the world. Stool culture is not recommended.

For GAS, the rapid antigen detection test (RADT) of the swab could be used, allowing a quicker diagnosis. Depending on the method of RADT, the sensitivity for extrapharyngeal GAS ranges from 77.9% to 98.0%, suggesting that this test may represent a rapid, practical and accurate diagnostic tool for point-of-care differentiation of GAS-associated PID from other conditions with similar presentations. A recent French prospective multicenter study showed RADT to have a sensitivity of 98% and a specificity of 72.8%. However, RADT does not have formal approval for extrapharyngeal testing. A negative RADT result needs additional testing by bacterial culture.

Sophisticated tests, like pulse field gel electrophoresis, allowing genotyping of the bacteria, are reserved for research studies, especially to determine if types of bacteria are identical in outbreaks.

DIAGNOSIS
As shown, with a high index of suspicion, the simple culture (or RADT) of the perianal skin confirms the PID diagnosis. Although most patients included in this review were seen primarily by their pediatrician or family physician, only three papers were published by pediatricians from primary healthcare facilities.

Most published reports diagnosing PID have come from dermatologists, working in dermatology university centers, or hospitals, as well as from those in pediatric dermatology university centers, or hospitals. Also, many of the patients were diagnosed by physicians from pediatric university centers or hospitals.

There were four reports of PID diagnosed in surgery services. Only one paper was published, respectively, by authors from a pediatric gastroenterology clinic, pediatric radiology clinic, pediatric infectious clinic, ear nose and throat clinic, and from an emergency medicine hospital.

Characteristically, a delay in diagnosis is reported by most authors (mean of 6 mo, ranging from 1 mo to 1 year). As such, many children undergo unnecessary investigations and therapies. A few reports showed a 2-year delay to diagnosis. However, diagnosis is sometimes established within 1 mo (e.g., 3 wk, 2 wk, 10 d, 1 wk, 3 d, and 2 d). Table 5 presents previous suspected diagnoses and performed tests in children with PID (including the present cases). As shown, PID was misdiagnosed most often as candidiasis, pinworms, anal fissure, psoriasis, sexual abuse, eczema, atopic dermatitis, constipation, Crohn’s disease, inflammatory bowel disease, ammoniacal diaper dermatitis, psychosomatic stool holding, threadworms, hemorroids, poor hygiene, perianal allergy, and gut dysbiosis. As seen, not only can misdiagnosis lead to improper therapies but also to potential severe consequences on family harmony and to legal issues. Just carrying out anal tests for pinworms appears far less erroneous, costly and/or invasive than performing lower and upper endoscopies under general anesthesia, upper gastrointestinal X-ray series and barium enema, as well as magnetic resonance enterography.

DIFFERENTIAL DIAGNOSIS
As anticipated from the previous paragraph, differential diagnosis of PID is vast and, unfortunately, patients are commonly overlooked. Besides the conditions already mentioned, differential diagnosis encompasses seborrheic dermatitis, Langerhans cell histiocytosis, zinc deficiency dermatosis, intertrigo, redness from vigorous wiping, fecal incontinence, and lichen planus.

DISEASE COURSE AND COMPLICATIONS
PID does not resolve spontaneously. The longer the time until correct diagnosis and therapy, the higher is the risk for discomfort and complications. Complications related to streptococcal infections include impetigo, and immunological conditions, like post-streptococcal acute glomerulonephritis (commonly known as PSAGN) and rheumatic fever. Although among the included studies, no such immunological complications were found, a urine analysis may be performed to screen for possible PSAGN. GAS-associated PID may trigger acute guttate psoriasis (GP) or pustular psoriasis or purpuric plaques. Treating PID also resolves the skin disease, as was mostly reported, except for 1 case of GP and 1 of plaque-psoriasis. Among the cases with GBS-associated PID, GP developed in 1 child and one adult. GP could be determined by stimulation of T cells by superantigens, in GAS infections; however, GBS do not produce superantigenic exotoxins. In patients with GP, the perianal/perineal area should be carefully inspected.
and cultured when appropriate, to exclude PID as a triggering factor\textsuperscript{[20,60]}.

**TREATMENT**

Since PID usually goes unrecognized for a long time, patients are erroneously treated for other conditions. The most used topical agents were antifungal agents\textsuperscript{[3,13,16,22,27,31-33,35,36,42,43,47,49,51,61,64,65]} and corticosteroids\textsuperscript{[3,4,8,10,19,22,28-30,33,40,41,56,60,61]} and other topical agents were represented by antibiotics\textsuperscript{[3,10,28,33,45,56]}, antiseptics, suppositories\textsuperscript{[10,28]}, zinc oxide\textsuperscript{[3,4,8]}, anesthetics\textsuperscript{[10,30]}, kenacutan\textsuperscript{[50]}, tannate\textsuperscript{[45]}, vitamins A and D\textsuperscript{[61]}, antihemorrhoidal and cicatirizants. Oral medication included laxatives\textsuperscript{[10,28,30]}, anthelmintics\textsuperscript{[10,33,65]}, antibiotics\textsuperscript{[4,33]}, nystatin\textsuperscript{[32,47]}, antihistaminic agents and probiotics. A survey on general practitioners from an area in the United Kingdom appears as very illustrative for the various modalities of managing this peculiar condition. After a case with PID was presented, physicians were asked what their management would be at the first consultation. Their answers included "anthelmintics (54%), stool softeners (52%), taking a perianal swab (31%), topical anesthetics (28%), antifungal cream (22%), looking for possible sexual abuse (17%), topical antiseptics (11%), systemic antibiotics (7%), and looking for inflammatory bowel disease (7%)"\textsuperscript{[47]}. This highlights PID as being largely unknown still; and, more worrisome, almost one-fifth of the general practitioners considered investigating for possible sexual abuse.

Conversely, an early correct antibiotic therapy leads to a dramatic and rapid improvement of symptoms, in 1 d\textsuperscript{[43]}, 2 d\textsuperscript{[2,13,37,39]} or 3 d\textsuperscript{[2,4,44,56]}, with reports showing healing of PID after 4 d\textsuperscript{[49,58]} (Tables 2 and 4). The actual goal of therapy is represented by complete healing (CH), meaning disappearance of clinical signs and eradication of perianal bacteria. CH has been reported 2 wk\textsuperscript{[4,9,14,30,61,62]} to 4 wk after starting therapy\textsuperscript{[47]}.

Two studies mentioned obtaining CH with topical antibiotics as a sole therapy (erythromycin\textsuperscript{[41]} and mupirocin\textsuperscript{[31]}); however, oral antibiotics are considered the medication of choice\textsuperscript{[13,25,79]}. Classically, the medication of choice against GAS consisted of oral penicillin (Pen)\textsuperscript{[2,4,8,10,12,17,20-22,25,27-30,33,37,45,46,50,53,59-63]} (Tables 2 and 4). Duration of Pen therapy ranged from 7 d\textsuperscript{[65]} to 10 d\textsuperscript{[2,4,6,8,12,17,20-22,25,27-30,33,36,37,44,45,62]}; 2 wk\textsuperscript{[8,22,33,53,61]}, 3 wk\textsuperscript{[10,29,61]} and 4 wk\textsuperscript{[22]}. Amoxicillin has been considered a good alternative\textsuperscript{[19,21,43]}, given for 6 d\textsuperscript{[54]}, 10 d\textsuperscript{[4,13,36,39,56,57]} or 2 wk\textsuperscript{[22]}. Other authors used cefadroxil\textsuperscript{[42]}, amoxicillin-clavulanate\textsuperscript{[11,17]}, erythromycin\textsuperscript{[22]}, or josamycin\textsuperscript{[55]}. In many cases, oral antibiotic was used in combination with a topical agent. Pen was associated with topical antibiotics (mupirocin\textsuperscript{[20,21,36,40]} or fucidin\textsuperscript{[9,10,30]}), or antiseptics (cloquinol\textsuperscript{[40]} or polyhexanid\textsuperscript{[48]}). Amoxicillin was combined with fucidin\textsuperscript{[30]} or mupirocin\textsuperscript{[14,36,38]} and amoxicillin-clavulanate with topical bactracin\textsuperscript{[11]}. As for macrolides, erythromycin was associated with mupirocin\textsuperscript{[55]} and spiramycin was used in the cases belonging to the present author, in combination with mupirocin and bactracin plus neomycin, respectively. Cefadroxil was associated with fucidin\textsuperscript{[41]} and cefuroxime with mupirocin\textsuperscript{[3]} or mupirocin\textsuperscript{[58]}. Cefuroxime plus topical fucidin was used in PID caused by GAS and S. aureus, by GBS and by GCS\textsuperscript{[3]}. In cases with S. aureus only, oral erythromycin and cephalixin were used\textsuperscript{[26,32]}.

It is quite difficult to appreciate the treatment efficacy, since some authors reported only clinical healing, while others considered CH and others did not mention the type of healing. CH was reported after Pen\textsuperscript{[22]}, amoxicillin\textsuperscript{[56]}, cefadroxil\textsuperscript{[42]}, Pen combined with fucidin\textsuperscript{[39]}, erythromycin with mupirocin\textsuperscript{[32]}, spiramycin with mupirocin or with bactracin plus neomycin. More details about the CH are presented in Tables 2 and 4\textsuperscript{[4,6,14,18]}.

Some patients required a second course of antibiotic, either to cure symptoms or to eradicate perianal bacteria, or both. Some authors preferred to use the same antibiotic (Pen\textsuperscript{[2,17,20,29]}, amoxicillin\textsuperscript{[22]} or cephalixin\textsuperscript{[49]}), detailed in Tables 2 and 4. Other authors chose a different antibiotic for the second course. After ineffective oral Pen, erythromycin\textsuperscript{[22,61]}, cefadroxil\textsuperscript{[27]} or clarithromycin\textsuperscript{[17,27]} determined CH. In a GCS-associated PID case, after oral cefuroxime plus topical fucidin being ineffective, oral amoxicillin lead to CH\textsuperscript{[3]}.

The only published RCT, by Meury et al\textsuperscript{[22]}, compared 15 children treated with oral Pen with 14 cases with cefuroxime, all with GAS-associated PID. Both clinical improvement and eradication of perianal GAS were significantly higher with cefuroxime versus Pen (Table 2). However, the study was not blinded and there was no follow-up after the end of treatment, precluding evaluation of optimal duration for the cefuroxime therapy\textsuperscript{[42]}.

**PROGNOSIS**

From the data presented, it appears that most cases are easy to cure (i.e., reaching CH). However, recurrence (clinical and/or bacteriological) may occur and a repeated course of antibiotics is required\textsuperscript{[6]}. Assessing recurrence rate appears rather difficult, as most cases did not have a precise follow-up period. No clinical recurrence was reported after oral Pen\textsuperscript{[30]}, amoxicillin-clavulanate\textsuperscript{[11]} and cefadroxil plus topical fucidin\textsuperscript{[11]}. No clinical and bacteriological recurrence was detected after topical mupirocin\textsuperscript{[31]} and josamycin\textsuperscript{[17]}. In the study by Kokx et al\textsuperscript{[49]}, the 39% relapses were treated with Pen. In children treated with amoxicillin plus mupirocin, the recurrence rate varied between 11%\textsuperscript{[14]} and 27%\textsuperscript{[18]}. In a series of 21 cases treated with oral Pen plus topical polyhexanid, only 5% showed recurrence\textsuperscript{[8]}.

In one of the largest published studies of GAS-associated PID (81 cases), recurrence was detected in 32% of cases, significantly higher after Pen or amoxicillin vs a beta-lactamase-resistant antibiotic (Table 2). A meta-analysis performed by the same authors showed that the pooled recurrence rate after Pen or amoxicillin was significantly higher than after a beta-lactamase-resistant antibiotic (odds ratio: 2.39, 95%CI: 1.18-4.81)\textsuperscript{[26]}.
the largest (157 cases with GAS-associated PID) and most recent series, patients were treated with various antibiotics. The clinical recurrence rate, 6 mo after the first episode, was much higher after using cephalaxin versus amoxicillin (Table 2). Recurrence after amoxicillin was predicted by a delayed diagnosis and having a sibling with PID around the time of the first episode[23].

Recurrences appearing soon after therapy may be due to poor compliance with antibiotics or their inadequate dosage. Alternatively, some recurrences could be the result of a reinfection in the context of a continuous exposure (intrafamilial or close contact), due to poor hygiene[24]. Therefore, in those with frequent relapses, it is recommended to screen (and eventually treat) other members of the family[25]. Improvement of personal (hands washing, individual use of toothbrush, towels, toilets, etc.) and collective hygiene is indispensable.

CONCLUSION
To the best of the author’s knowledge, this is the first narrative review of all published available pediatric cases with PID, to date. Although the clinical characteristics of PID are well-defined, it still remains a misdiagnosed entity, with an underestimated frequency. PID could appear at any age and affect females as well. Given its infectious origin, PID may have intra- and/or interfamily spread. The vast majority of cases are caused by GAS; however, other BHS (like GBS, GCS and GGS) and S. aureus have been described. These bacteria could also be found in the upper respiratory tract. Since PID may mimic other common conditions with skin manifestations, laboratory tests are required for correct diagnosis. RADT could suffice to identify GAS, but bacterial culture is the most reliable tool for diagnosis. If not properly diagnosed and treated, PID has a chronic, unremitting course.

Oral Pen or amoxicillin could be used for the initial treatment of BHS-associated PID; however, the recurrence rate is high (up to 40%). Various beta-lactamase-resistant antibiotics could be used instead (like cephalosporines, amoxicillin-clavulanate, macrolides and clindamycin). Combining oral antibiotics with topical antiseptics or antibiotics may accelerate bacterial clearance. Duration of therapy should be 14–21 d. Therapeutic efficacy should be appreciated both clinically and bacteriologically; throat culture should also be repeated, if it was positive. Recurrence rates of PID remain high. Improvement of personal and collective hygiene is essential.

RESEARCH PERSPECTIVES
Prospective well-designed (multicenter) clinical trials are required in order to detect the incidence of this condition. Moreover, randomized controlled studies, with adequate follow-up, should be performed in order to formulate the optimum personalized antibiotic therapy (oral alone or in association with topical medication) able to induce complete healing and prevent recurrences. An interesting topic of future research will be determining whether the same bacteria cause recurrences.

REFERENCES
1. Juern AM, Drolet BA. Cutaneous bacterial infections. In: Klingman RM, Stanton BF, St. Geme III JW, Schor NF, editors. Nelson Textbook of Pediatrics. 20th ed. Philadelphia: Elsevier; 2016: 3209
2. Amren DP, Anderson AS, Wannamaker LW. Perianal cellulitis associated with group A streptococci. Am J Dis Child 1966; 112: 546-552 [PMID: 5928818 DOI: 10.1001/archpedi.1966.020001500000077]
3. Zhang C, Haber RM. The ABCs of Perianal Streptococcal Dermatitis. J Cutan Med Surg 2017; 21: 102-107 [PMID: 27628908 DOI: 10.1177/1203475416670369]
4. Koks NP, Comstock JA, Facklam RR. Streptococcal perianal disease in children. Pediatrics 1987; 80: 659-663 [PMID: 3313256]
5. Mogieltcki NP, Schwartzman JD, Elliott JA. Perineal group A streptococcal disease in a pediatric practice. Pediatrics 2000; 106: 276-281 [PMID: 10920151 DOI: 10.1542/peds.106.2.276]
6. Eccheverría Fernández M, López-Menchero Oliva JC, Martín-Pardillo R, Miguez Navarro C, Sánchez Sánchez C, Vázquez López P. Isolation of Group A beta-hemolytic Streptococcus in children with perianal dermatitis. An Pediatr (Barc) 2006; 64: 153-157 [PMID: 16520768 DOI: 10.1157/13084175]
7. Lehman R, Pinder S. Streptococcal perianal infection in children. BMJ 2009; 338: b1517 [PMID: 19416994 DOI: 10.1136/bmj.b1517]
8. Jongen J, Eberstein A, Peleikis HG, Kahlikh V, Herbst RA. Perianal streptococcal dermatitis: an important differential diagnosis in pediatric patients. Dis Colon Rectum 2008; 51: 584-587 [PMID: 18324440 DOI: 10.1016/S0010-5053(07)60776-7]
9. Herbst RA, Hoch O, Kapp A, Weiss J. Guttate psoriasis triggered by perianal streptococcal dermatitis in a four-year-old boy. J Am Acad Dermatol 2000; 42: 885-887 [PMID: 10767696 DOI: 10.1016/S0190-9622(00)90263-9]
10. Grant HW, MacKinnay LA, Bisset WH, Utrley WS. Perianal cellulitis in children caused by group A streptococci. Pediatr Surg Int 1993; 8: 410-411 [DOI: 10.1007/BF00176730]
11. Wright JE, Buttl HL. Perianal infection with beta haemolytic streptococci. Arch Dis Child 1994; 70: 145-146 [PMID: 8129441 DOI: 10.1136/adc.70.2.145]
12. Meuny SN, Erb T, Schaad UB, Heininger U. Randomized, comparative efficacy trial of oral penicillin versus cefuroxime for perianal streptococcal dermatitis in children. J Pediatr 2008; 153: 799-802 [PMID: 18692203 DOI: 10.1016/j.peds.2008.06.035]
13. Souillet AL, Truchot F, Jullien D, Dumas V, Faure M, Floret D, Clauvy A. [Perianal streptococcal dermatitis]. Arch Pediatr 2000; 7: 1194-1196 [PMID: 11099460 DOI: 10.1016/S0903-6012(00)029-99]
14. Bardali A, Choon HA. Isolation of group A streptococci from children with perianal cellulitis and from their siblings. Pediatr Infect Dis J 1998; 17: 358-360 [PMID: 9576401 DOI: 10.1097/00006454-199804000-000024]
15. Mostafa WZ, Arnaout HH, el-Lawindi MI, el-Abidin YM. An epidemiologic study of perianal dermatitis among children in Egypt. Pediatr Dermatol 1997; 14: 351-354 [PMID: 9336803 DOI: 10.1111/j.1525-1470.1997.tb0079.x]
16. Cohen R, Levy C, Bonacorsi S, Wollner A, Koskas M, Jung C, Béchet S, Chalumeau M, Cohen J, Bidet P. Diagnostic accuracy of clinical symptoms and rapid diagnostic test in group A streptococcal perianal infections in children. Clin Infect Dis 2015; 60: 267-270 [PMID: 25313248 DOI: 10.1093/cid/ciu394]
17. Landolt M, Heininger U. Prevalence of perianal streptococcal dermatitis in children and adolescents. Praxis (Bern 1994) 2005; 94: 1467-1471 [PMID: 16209362 DOI: 10.1024/0369-8934.94.38.1467]
18. Shouval DS, Schurt D, Nussinovitch M. Presentation of perianal group a streptococcal infection as irritability among children. Pediatr Dermatol 2008; 25: 568-570 [PMID: 18950404 DOI: 10.1111/j.1525-1470.2008.00737.x]
19. Mateo JR, Carrero González PA, Pérez ES. Dermatitis estreptocócica perianal. Actas Dermosifiliogr 2002; 93: 243-246 [DOI: 10.1016/S0001-7310(02)76565-4]
20. Krol AL. Perianal streptococcal dermatitis. Pediatr Dermatol 1990; 7: 97-100 [PMID: 2359737 DOI: 10.1111/j.1525-1470.1990.tb0062x]
Garcia Osés I, Martínez de Zubarte Fernández JM, Puig García C, Armal Alonso JM. Pensando en la dermatitis perianal. *Pediatría Atención Primaria* 2015; 17: 51-55 [DOI: 10.4321/S1397-76222015001000012]

Patziri A, Costa AM, Fiorillo L, Neri I. Perianal streptococcal dermatitis associated with guttate psoriasis and/or balanoposthitis: a study of five cases. *Pediatr Dermatol* 1994; 11: 168-171 [PMID: 8041660 DOI: 10.1111/j.1525-1470.1994.tb00574.x]

Clegg HW, Gifts PM, Anderson WE, Kaplan EL, Johnson DR. Clinical Perianal Streptococcal Infection in Children: Epidemiologic Features, Low Symptomatic Recurrence Rate after Treatment, and Risk Factors for Recurrence. *J Pediatr* 2015; 167: 687-93.e1-2 [PMID: 26095284 DOI: 10.1016/j.jpeds.2015.05.034]

Šterbene A, Seme K, Lah LL, Točkova O, Kamhi Trop T, Švent-Kučina N, Pirš M. Microbiological characteristics of perianal streptococcal dermatitis: a retrospective study of 105 patients in a 10-year period. *Acta Dermatovenerol Alp Panoncina Adriat* 2016; 25: 73-76 [PMID: 28006879 DOI: 10.15570/acacta.2016.21]

Olson D, Edmonson MB. Outcomes in children treated for perianal group A beta-hemolytic streptococcal dermatitis. *Pediatrics* 1988; 82: 113-114 [PMID: 3381270 DOI: 10.1542/peds.82.1.113-c]

Edmonson MB. Outcomes in children treated for perianal streptococcal dermatitis. *Pediatrics* 2000; 106: 695-700 [PMID: 10743579 DOI: 10.1542/peds.106.4.695-a]

October 25, 2018 | Volume 7 | Issue 4 | 103

Serban ED. PID: Underdiagnosed and unremitting
Anusitis associated with group A beta-hemolytic streptococcal dermatitis/disease: recognition and management. Am J Clin Dermatol 2003; 4: 555-560 [PMID: 12862498 DOI: 10.1016/S1202-870-2003-01979-0]

Bronberg A, Mobacken H. Perianal streptococcal dermatitis is a possibility in therapy-resistant anal redness. Lakartidningen 1992; 89: 3955-3956 [PMID: 1461011]

Teillac-Hamel D, de Piro Y. Perianal streptococcal dermatitis in children. Eur J Dermatol 1992; 2: 71-74

Neri I, Bardazzi F, Marzaduri S, Patrizi A. Perianal streptococcal dermatitis in adults. Br J Dermatol 1996; 135: 796-798 [PMID: 8977685 DOI: 10.1046/j.1365-2133.1996.d01-1082.x]

Scheiba N, Sanz G, Perez C, Vidal J. Beta-hemolytic streptococci in children with streptococcal pharyngitis. Pediatr Infect Dis J 1996; 15: 749-752 [PMID: 8690126 DOI: 10.1097/00001610-199608000-00014]

Abdolrasouli A, Hartschuh W. Perianal streptococcal dermatitis caused by group B streptococci [Turkish]. Turkish J Dermatology [Internet] 2009; 3: 70-72

Kallini JR, Cohen PR. Perianal and periurethral dermatitis: Report of a woman with group G streptococcal infection and review of perianal and periurethral dermatoses. Dermatol Online J 2013; 19: 3 [PMID: 24021363]

Mcintyre DM. An epidemic of Streptococcus pyogenes puerperal and postoperative sepsis with an unusual carrier site--the anus. Am J Obstet Gynecol 1968; 101: 308-314 [PMID: 4967751 DOI: 10.1016/0002-9378(68)90056-2]

Schaffner W, Lefkowitz LB Jr, Goodman JS, Koenig MG. Hospital outbreak of infections with group A streptococci traced to an asymptomatic anal carrier. N Engl J Med 1969; 280: 1224-1225 [PMID: 4889553 DOI: 10.1056/NEJM196905292801225]

Anses RS, Vail D, Grehin B, Sprunt K. Anal carrier rate of group A beta-hemolytic streptococci in children with streptococcal pharyngitis. Pediatrics 1973; 52: 439-441 [PMID: 4581122]

Clegg HW, Dallas SD, Roddye OF, Martin ES, Swettenham RL, Koonce EW, Felkner MB, Ryan AG; Presbyterian Pediatric Research Group. Extrapharyngeal group A streptococcal infection: diagnostic accuracy and utility of rapid antigen testing. Pediatr Infect Dis J 2003; 22: 726-731 [PMID: 12913775 DOI: 10.1097/01.inf.0000078835.72497.ab]

P- Reviewer: Agrawal A, Nkachukwu SN  S- Editor: Ji FF  L- Editor: A  E- Editor: Yin SY
